Cure Network Dolby Acceleration Partners LLC (CNDAP) was founded in 2015 as a partnership between Cure Network Ventures, a corporation wholly owned by Gladstone Institutes, and the Dolby family office. CNDAP promotes the translational advancement of Gladstone’s fundamental discoveries by bridging the gap between academia and industry. Its main focus is the discovery of small molecules and other therapeutics that could transform the treatment of Alzheimer’s disease and related neurological disorders. CNDAP’s operating model matches promising scientific programs that are ready for translation with suitable funding sources and serves as a catalyst for the establishment of spin-out companies and partnerships with biotech and pharma companies. CNDAP was founded around two innovative research programs using distinct approaches for the treatment of Alzheimer’s disease, which originated in the labs of Lennart Mucke, MD, and Jorge Palop, PhD, at Gladstone Institutes.